Pulmonx Co. (NASDAQ:LUNG) Receives $14.67 Average Price Target from Analysts

Shares of Pulmonx Co. (NASDAQ:LUNG) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $14.67.

A number of equities research analysts have recently issued reports on LUNG shares. Wells Fargo & Company cut their price target on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Stifel Nicolaus cut their target price on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Finally, Canaccord Genuity Group raised their target price on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st.

Insider Buying and Selling at Pulmonx

In other news, insider Geoffrey Beran Rose sold 4,586 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total transaction of $30,726.20. Following the transaction, the insider now owns 295,433 shares in the company, valued at $1,979,401.10. This represents a 1.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $8.09, for a total transaction of $161,800.00. Following the completion of the sale, the director now directly owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. The trade was a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,351 shares of company stock valued at $361,494 in the last quarter. Company insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Pulmonx

Institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC lifted its position in Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after acquiring an additional 104,432 shares during the last quarter. Sei Investments Co. boosted its stake in Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock valued at $673,000 after purchasing an additional 1,800 shares during the period. SG Americas Securities LLC acquired a new stake in Pulmonx in the 3rd quarter valued at approximately $102,000. XTX Topco Ltd bought a new position in Pulmonx in the 2nd quarter worth approximately $222,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after buying an additional 69,595 shares during the last quarter. Institutional investors own 91.04% of the company’s stock.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $6.61 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The company has a market capitalization of $261.03 million, a PE ratio of -4.50 and a beta of 0.68. The stock has a fifty day moving average of $7.04 and a 200-day moving average of $7.09. Pulmonx has a one year low of $5.46 and a one year high of $14.84.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same quarter last year, the company posted ($0.39) EPS. As a group, equities analysts anticipate that Pulmonx will post -1.53 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.